A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma

Status
Approved-not yet active
Cancer Type
Multiple Myeloma
Trial Phase
Phase II
Phase III
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01602224
Protocol IDs
14199 (primary)
H9S-MC-JDCG
Study Sponsor
Eli Lilly and Company

Summary

The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.

Treatment Sites in Georgia


Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Study Coordinator:
Alaina Mitchell
404-778-5747